Managing Relapsing-Remitting Multiple Sclerosis: The Role of the Pharmacist

Managing Relapsing-Remitting Multiple Sclerosis: The Role of the Pharmacist

Faculty Presenter

Amanda Hickman, PharmD, MPH, MSCS
Central Support Neuro/Psych Pharmacist
Neuro/Psych Subcommittee Chair
Trellis Rx
Atlanta, Georgia
 
Program Description
Multiple sclerosis (MS) often presents in a relapsing-remitting (RR) disease course that is classified by inflammatory attacks or exacerbations followed by periods of partial or complete remission. Patients with RRMS experience significant financial burdens as well as decreased quality of life due to disease relapses. Pharmacists can be instrumental in identifying patients for whom early treatment of RRMS with disease-modifying therapies (DMTs) may be beneficial. This activity will review different mechanisms of action, adverse effects, and costs of recently approved DMTs. Key challenges surrounding treatment administration and access have been exacerbated by COVID-19, such as disruption in monitoring or missed infusions, and have affected patient adherence. Strategies for pharmacist interventions to improve overall patient outcomes in RRMS utilizing telemedicine will be presented.  

Target Audience: Specialty pharmacists
Type of Activity: Application
Release date: August 26, 2021
Expiration date: August 26, 2022
Estimated time to complete activity: 1.0 hour
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Examine multiple sclerosis, specifically relapsing-remitting multiple sclerosis (RRMS), and its prevalence, pathology, etiology, prognosis, and implications of COVID-19
• Determine the goals of RRMS treatment along with the most recent data on available disease-modifying therapies and lifestyle modifications to reduce burden of disease
• Explore opportunities for pharmacist interventions using telehealth and narrowing health care disparities in RRMS treatment and management

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-21-317-H01-P. The activity is available for CE credit through August 26, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webinar in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Faculty
Amanda Hickman, PharmD, MPH, MSCS, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Michelle C. Carlson, PharmD; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Activity Disclaimer
Pharmacy Times Continuing Education™ (PTCE) strives to provide the highest level of service. However, unforeseen circumstances may necessitate the rescheduling or cancellation of live events, including, but not limited to, webinars hosted by PTCE. PTCE reserves the right to cancel an event without notice. PTCE will not be responsible for any expenditure incurred due to the cancellation.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this live CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms